炎症免疫综合指数在免疫检查点抑制剂治疗肺癌患者中的预测价值及模型构建OA
Predictive value and model construction of inflammatory immune compos-ite index in lung cancer patients treated with immune checkpoint in-hibitors
目的 探讨基于外周血炎症指标构建的炎症免疫综合指数(IICS)对接受免疫检查点抑制剂治疗的非小细胞肺癌(NSCLC)患者的预后预测价值.方法 回顾性收集 2021 年 1 月至 2023 年 1 月石河子大学第一附属医院收治的接受免疫治疗的 157 例NSCLC患者的临床资料,通过ROC曲线确定炎症标志物截断值并构建IICS,采用Ka-plan-Meier法和Cox回归分析其预后意义并用R语言构建预测模型,采用校正曲线对预测模型进行内部验证.结果 截至随访结束,157 例患者中失访 8 例,随访率为 91.08%.完成随访(包括记录死亡终点的患者)的 149 例患者中,根据预后分组,生存组 84 例,死亡组 65 例.两组患者的基线美国东部肿瘤协作组体能状态(ECOG PS)评分、远处转移、泛免疫炎症值(PIV)、血小板-淋巴细胞比值(PLR)、全身免疫炎症指数(SII)、全身炎症反应指数(SIRI)、血小板-白蛋白比值(PAR)、预后营养指数(PNI)、淋巴细胞-单核细胞比值(LMR)和晚期肺癌炎症指数(ALI)比较,差异有统计学意义(P<0.05).根据各炎症指标构建IICS,该IICS对接受免疫治疗的NSCLC患者具有预后预测价值,AUC为 0.71(95%CI:0.62~0.79,P<0.001),最佳截断值为>3.生存分析显示,与高IICS患者相比,基线低IICS患者的无进展生存期(PFS)更长(P<0.001).多因素Cox回归分析结果显示,年龄、吸烟史、ECOG PS评分、远处转移、IICS为预后的独立影响因素(P<0.05).基于此构建的预测模型在预测 1 年PFS率时AUC为0.84(95%CI:0.73~0.87),校准曲线表明模型拟合良好.结论 基于IICS构建的预测模型对免疫治疗NSCLC患者的预后评估具有重要价值,有助于临床个体化决策.
Objective To investigate the prognostic value of comprehensive inflammatory immune composite index(IICS)based on peripheral blood inflammatory markers in non-small cell lung cancer(NSCLC)patients treated with immune checkpoint inhibitors.Methods The clinical data of 157 NSCLC patients who received immunotherapy in the First Affiliated Hospital of Shihezi University from January 2021 to January 2023 were retrospectively collected.The cut-off values of in-flammatory markers were determined by ROC curve and IICS were constructed.Kaplan-Meier method and Cox regression were used to analyze the prognostic significance,and R language was used to construct the prediction model.The calibration curve was used to internally verify the prediction model.Results By the end of follow-up,8 of 157 patients were lost to follow-up,and the follow-up rate was 91.08%.A total of 149 patients who completed follow-up(including those with death endpoint recorded)were divided into sur-vival group(84 cases)and death group(65 cases)according to the prognosis.There were significant differences in the baseline Eastern Cooperative Oncology Group performance status(ECOG PS)scores,distant metastasis,pan-immune inflammation value(PIV),platelet-to-lymphocyte ratio(PLR),systemic immune inflammation index(SII),systemic inflam-mation response index(SIRI),platelet-to-albumin ratio(PAR),prognostic nutritional index(PNI),lymphocyte-to-monocyte ratio(LMR),and advanced lung cancer inflammation index(ALI)between the two groups(P<0.05).The constructed IICS based on the inflammatory indexes had prognostic value for NSCLC patients receiving immunotherapy.The AUC was 0.71(95%CI:0.62-0.79,P<0.001),and the best cut-off value was>3.Survival analysis showed that patients with low baseline IICS had longer progression free survival(PFS)than those with high IICS(P<0.001).Multivariate Cox regression analysis showed that age,smoking history,ECOG PS score,distant metastasis,and IICS were independent prognostic factors(P<0.05).The AUC of the prediction model for 1-year PFS rate was 0.84(95%CI:0.73-0.87),and the calibration curve showed that the model fitted well.Conclusion The prediction model based on IICS is of great value for the prognosis evaluation of NSCLC patients treated with immunotherapy,which is helpful for clinical individualized decision-making.
李晗婧;张权林;李静;杨振兵
石河子大学药学院,新疆石河子 832003新疆维吾尔自治区石河子市人民医院药剂科,新疆石河子 832000石河子大学第一附属医院药学部,新疆石河子 832008石河子大学药学院,新疆石河子 832003
医药卫生
非小细胞肺癌免疫治疗炎症免疫综合指数外周血炎症指标列线图
Non-small cell lung cancerImmunotherapyInflammatory immune composite indexPeripheral blood in-flammation indexNomogram
《中国当代医药》 2026 (4)
9-15,7
石河子大学科研计划项目(JCYJ202308).
评论